While the drop in Ultragenyx stock certainly provides a lower entry point for new investors, the more prudent choice right ...

Notified in December 2023, the revised Schedule M has shifted the focus from “good manufacturing practices” to “good ...

Ambros Therapeutics launches with $125M to advance neridronate, a non-opioid therapy for CRPS-1. See how this Phase 3-ready ...

For most drugmakers, the US is the largest single market. Prices there are often close to three times higher than in other ...

After raising $293 million in the IPO, Insilico Medicine aims to become “a massive source of innovative drugs for pharma ...

Ultragenyx Pharmaceutical (RARE) remains a Sell after its Phase 3 OI program failed to meet primary fracture reduction ...

Intas has signed an exclusive agreement with SII-backed IntegriMedical to deploy needle-free injection systems across IVF ...

New institution, envisioned by the late businessman Petch Osathanugrah, boosts Thai capital as burgeoning art destination ...

Extrawell Pharmaceutical Holdings Limited ( ($HK:0858) ) has shared an update. Extrawell Pharmaceutical Holdings Limited, a Hong Kong-listed ...

Explore the challenges faced by Indian pharma in developing rare disease drugs and potential solutions for innovation and cost reduction.

Several Indian companies are preparing to launch generic versions of GLP-1 category drug Semaglutide in India ...

Ultragenyx Pharmaceutical said on Monday that late-stage studies showed its drug for a type of genetic bone disease failed to ...